Videos

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Lau discusses the use of virtual shared medical appointments for increasing access to cardiovascular care in a traditionally underserved population.

Vogelmeier discusses major changes to the annual COPD report, including a broader threshold for escalating treatment after exacerbation.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

COPD is not a complex disease, Polverino explains. It's only complex to treat because of limited understanding.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Polverino stresses the need for prospective analysis to validate CC16 and mucus plugs as viable biomarkers for COPD status.

Bakhos explains the ideal patient population and strategies inherent to LVRS success.

Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Lau discusses the importance of developing and applying technology to predict potential adverse cardiovascular outcomes in pregnant patients.

At ACAAI 2025, Adatia discussed interim KONFIDENT-KID trial findings showing oral sebetralstat safely reduced symptom burden in pediatric HAE.

Gatti highlights the role of social media in dermatology, noting its importance for business growth but emphasizing the need to focus on education.

At ACAAI 2025, Harris spoke with HCPLive about Excellergy’s ECRI program, exploring IgE modulation, safety goals, and potential long-term effects in CSU.

Alkhouri breaks down recent therapeutic progress in MASH and explains new data on resmetirom’s use in patients with compensated MASH cirrhosis.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

Kremer breaks down new data on the disease-modifying and symptom-relieving effects of seladelpar presented at AASLD The Liver Meeting 2025.

GLISTEN AASLD-presented data show linerixibat reduces biomarkers and itch in PBC, supporting the drug as an ileal bile acid transporter inhibitor.

In this interview with Nguyen, Nguyen highlights takeaways from From 'Basement Membrane to Bedside: The Science & Strategy of Bullous Diseases.'

Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.

At ACAAI 2025, Harris discussed research on novel mechanism known as allergic effector cell response inhibitors.

Younossi explains the importance of patient-reported outcomes and assessing HRQoL, breaking down findings from an analysis of the MAESTRO-NAFLD trial of resmetirom.

Kremer describes recent advancements in the PBC treatment landscape and reviews findings from abstracts on elafibranor presented at AASLD The Liver Meeting 2025.

McGill emphasizes new exciting data shared at ACR 2025.